Physician profile
Robert Gutierrez
NPI 1922193895
$7,059.38
in general payments reported to CMS, 2019-2025
23 companies · $901 in 2025
The $901 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $908 · 2021: $1,887 · 2022: $968 · 2023: $772 · 2024: $727 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,007.50 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,173.23 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $828.27 | 2020-2025 | Xifaxan |
| Lilly USA, LLC | $516.12 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $361.17 | 2021-2025 | |
| Amarin Pharma, INC. | $310.25 | 2019-2022 | |
| Pfizer INC. | $306.60 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.43 | 2021-2025 | Jardiance |
| Portola Pharmaceuticals, LLC | $233.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $175.70 | 2020-2023 | |
| Radius Health, INC. | $146.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $102.47 | 2020-2024 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $101.10 | 2021-2025 | Zoryve |
| Amgen INC. | $93.58 | 2019-2021 | |
| Eisai INC. | $70.00 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $67.90 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $66.94 | 2025 | Voquezna |
| Abbott Laboratories | $60.66 | 2022-2023 | Freestyle Libre 3 |
| Ethicon US, LLC | $46.61 | 2019 | |
| Abbvie INC. | $45.35 | 2021-2022 | |
| Exact Sciences Corporation | $24.81 | 2025 | The Cologuard Plus Collection Kit |
| Allergan, INC. | $18.01 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.11 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.